EGEN, a clinical stage biopharmaceutical company, has commenced a Phase I trial of EGEN-001, an immunotherapy agent for the treatment of advanced ovarian cancer.
The study evaluates EGEN-001, in combination with pegylated liposomal doxorubicin (Lipodox), for the treatment of recurrent ovarian cancer.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
EGEN president and CSO Dr Khursheed Anwer said the trial will progress the testing of EGEN-001 with an approved second-line treatment for platinum-resistant ovarian cancer.
"Long-term treatment with an immune modulating agent in conjunction with cytotoxic agents is a promising approach to combatting difficult to treat cancers," Anwer said.
EGEN-001 uses the company’s TheraPlas delivery technology and is composed of interleukin-12 (IL-12) gene, formulated with a biocompatible delivery polymer.
IL-12 cytokine works by enhancing the body’s immune system against cancer and inhibiting tumor blood supply.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe immunotherapy agent is also being assessed as a single agent in a Phase II clinical trial for the treatment of platinum-resistant ovarian cancer and as a combination therapy with chemotherapeutic agents subsequent to cytoreductive surgery and HIPEC therapy in colorectal cancer.
A network of researchers, led by the Gynecologic Oncology Group (GOG) at member institutions under an agreement between the GOG and EGEN, are conducting the EGEN-sponsored trial.
Image: A pathological specimen of ovarian carcinoma. Photo: Courtesy of Jmh649.
